| Half-life | 1.7 days |
| Tmax | 6 h |
| Protein Binding | 97 % |
| Volume of Distribution | 423 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Take with food to improve tolerability; strong CYP3A substrate and inhibitor. |
Severity: Moderate
Adverse Effects:
Severe GI toxicity (diarrhea, nausea), hepatotoxicity, QT prolongation, hyperglycemia
Contraindications:
Severe hepatic impairment
Precautions:
ECG and glucose monitoring; reduce dose if intolerable
Half-life ~41 hours ≈ 1.7 days
Max dose often 450 mg/day with food